Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America

BACKGROUND: Efavirenz (EFV) and boosted protease inhibitors (bPIs) are still the preferred options for firstline antiretroviral regimens (firstline ART) in Latin America and have comparable short-term efficacy. We assessed the long-term durability and outcomes of patients receiving EFV or bPIs as fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Caro-Vega, Yanink, Belaunzarán-Zamudio, Pablo F, Crabtree-Ramírez, Brenda E, Shepherd, Bryan E, Grinsztejn, Beatriz, Wolff, Marcelo, Pape, Jean W, Padgett, Denis, Gotuzzo, Eduardo, McGowan, Catherine C, Sierra-Madero, Juan G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836274/
https://www.ncbi.nlm.nih.gov/pubmed/29527539
http://dx.doi.org/10.1093/ofid/ofy004

Ejemplares similares

Ejemplares similares